Wednesday, 9th of November 2011 |
Abstract below. Full text, to subscribers of AJTMH, is at
http://www.ajtmh.org/content/85/5/826.abstract?etoc
Costs of Integrated Mass Drug Administration for Neglected Tropical Diseases in Haiti
1. Ann S. Goldman*, Molly A. Brady, Abdel Direny, Luccene Desir, Roland Oscard,
Jean-Francois Vely†, Mary Linehan and Margaret Baker
+ Author Affiliations
+ Author Notes
Authors' addresses: Ann S. Goldman, Department of Epidemiology and Biostatistics, George Washington School of Public Health and Health Services, Washington, DC, E-mail: sphasg@gwumc.edu. Molly A. Brady, RTI International, Washington, DC, E-mail: mollyabrady@gmail.com. Abdel Direny, NTD Country Program Manager, IMA World Health, Hôpital Saint Francois de Sales, Port-au-Prince, Haiti, E-mail: abdeldireny@imaworldhealth.org. Luccene Desir, Hôpital Ste. Croix, Leogane, Haiti College of Science, Haiti Program University of Notre Dame Notre Dame, IN, E-mail: Luccene.Desir.2@nd.edu. Roland Oscard, Coordonnateur Programme National de Contrôle de la Malaria, Ministère de la Santé Publique et de la Population, 111 Rue St. Honore Hôpital Militaire, Port-au-Prince, Haiti, E-mail: Roroscar@yahoo.fr. Mary Linehan, U.S. Agency for International Development/Indonesia, American Embassy, Jl, Medan Merdeka Selatan, No. 5, Jakarta 10110, Indonesia, E-mail: marylinehan609@gmail.com. Margaret Baker, Department of International Health, School of Nursing and Health Studies, Georgetown University, Washington, DC, E-mail: mcb93@georgetown.edu.
↵†Deceased.
Abstract.
We conducted a cost analysis of Haiti's Ministry of Public Health and Population neglected tropical disease program, Projet des Maladies Tropicales Negligées and collected data for 9 of 55 communes participating in the May 2008–April 2009 mass drug administration (MDA). The Projet des Maladies Tropicales Negligées Program partnered with IMA World Health and Hôpital Ste. Croix to implement MDA for treatment of lymphatic filariasis and soil-transmitted helminthiasis by using once a year treatment with albendazole and diethylcarbamazine in a population of approximately 8 million persons. Methods included analyzing partner financial records and conducting retrospective surveys of personnel. In the nine communes, 633,261 persons were treated at a cost of U.S. $0.64 per person, which included the cost of donated drugs, and at a cost of U.S. $0.42 per person treated, when excluding donated drug costs. The MDA for lymphatic filariasis in Haiti began in 2000, with the treatment of 105,750 persons at a cost per person of U.S. $2.23. The decrease in cost per person treated is the result of cumulative implementation experience and economies of scale.
Disclaimer: The contents of this article are the responsibility of the authors and do not necessarily reflect the views of the US Agency for International Development or the United States Government.
Footnotes
Financial support: This study was supported by the US Agency for International Development, as part of the Neglected Tropical Disease Control Program led by RTI International.
Are three drugs for malaria better than two?
Friday, 24th of April 2020 |
Public health Interventions and epidemic intensity during the 1918 influenza pandemic
Thursday, 16th of April 2020 |
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
Tuesday, 17th of March 2020 |
Using models to shape measles control and elimination strategies in low- and middle-income countries: A review of recent applications
Monday, 17th of February 2020 |
Immunization Agenda 2030
Tuesday, 11th of February 2020 |
40761705 |
www.measlesinitiative.org www.technet21.org www.polioeradication.org www.globalhealthlearning.org www.who.int/bulletin allianceformalariaprevention.com www.malariaworld.org http://www.panafrican-med-journal.com/ |